Skip to content
Open access

ZNF217 promotes receptor tyrosine kinase plasticity and AXL-ERK dependency in ovarian cancer

Sep 2026 · bioRxiv · 0 citations
Biology Medicine

TL;DR

It is shown that ZNF217 overexpression markedly increases ERBB2 levels in ovarian cancer cells, suggesting its potential as a biomarker to identify ovarian tumors that will respond to ERBB2-targeted therapeutics.

Abstract

ZNF217 is a potent oncogene that drives ovarian cancer progression and therapeutic resistance. We show that ZNF217 overexpression markedly increases ERBB2 levels in ovarian cancer cells, suggesting its potential as a biomarker to identify ovarian tumors that will respond to ERBB2-targeted therapeutics. Unexpectedly, ZNF217-high ovarian cancer cells exhibit resistance to multiple ERBB2 inhibitors, revealing a disconnect between receptor abundance and drug sensitivity. Mechanistically, ZNF217 drives chemoresistance by elevating the expression of several key receptor tyrosine kinases, most notably AXL, that activates MAPK signaling. Further, ZNF217 also upregulates ERK1/2 levels in ovarian cancer cells. This induces rewiring of downstream signaling, promoting an ERK-dominant state that sustains survival despite ERBB2 inhibition. Therapeutic targeting of the AXL–ERK axis reduced cell viability and metastatic potential in vitro, while suppressing tumor burden and prolonging survival in xenograft models. Thus, by elevating the expression of several key signaling receptors and their downstream effectors in ovarian cancer cells, ZNF217 establishes signaling plasticity that defines a novel mechanism of chemoresistance. These findings identify ZNF217 as a key determinant of signaling state and drug response and provides rationale to evaluate targeting AXL and ERK signaling in ZNF217-high ovarian tumors.

Read PDF

Similar papers

Open access Oct 2026

Oncogenic KRAS-MAPK signaling sustains a CD73 dependent therapeutic vulnerability in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is predominantly driven by oncogenic KRAS signaling and sustained by a desmoplastic, immunosuppressive microenvironment limiting therapeutic response. CD73-mediated adenosine signaling supports this immune-excluded, tumor-supportive microenvironment. Whether dual targeting of KRA...

Khadija Turabi, Urvinder Kaur Sardarni, Katherine E. Ankenbauer et al. · 0 citations
Review Oct 2026

RIPK1 kinase and scaffold activities in tumor cell fate and therapy.

Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in regulating cell survival and death, thereby exerting complex and multifaceted functions in the initiation and progression of cancer. Its expression is frequently dysregulated across diverse malignancies and correlates strongly with poor prognosis, hi...

Jing-Yu Luo, Shu-Ya Song, Ze-Kun Li et al. · 0 citations
Review Open access Oct 2026

SHP2 in Cancer: From Tumor Biology to Therapeutic Targeting.

SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA re...

Maryam Jama, M. Overduin, K. Barakat · 0 citations
Open access Oct 2026

DYRK1B overexpression promotes senescence-like transcriptional and secretory programs in A549 lung cancer cells.

The dual-specificity tyrosine-regulated kinase DYRK1B is frequently expressed at elevated levels in solid tumors and has been implicated in cancer cell survival, therapy resistance, and cell cycle arrest. While DYRK1B is best known for maintaining quiescence, its broader impact on cancer cell phenotypic plasticity rema...

G. Wilms, Aaron Babendreyer, Justyna Wozniak et al. · 0 citations
Open access Nov 2026

Protein Tyrosine Phosphatase 4A3 (PTP4A3) as a Prognostic Biomarker and Pharmacological Target in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) represents a critical focus for biomarker research, given its high mortality, rapid progression, substantial treatment resistance, and marked genetic heterogeneity. The present study identifies PTP4A3 as a relevant molecular determinant in the disease, linking its overexpression to advers...

Natália Sudan Parducci, Maria Fernanda Lopes Carvalho, I. C. Santos et al. · 0 citations
Open access Nov 2026

USP14-mediated deubiquitination stabilizes integrin β1 to sustain malignant progression and chemotherapy resistance in osteosarcoma

Osteosarcoma patients with metastasis or chemotherapy resistance typically have a poor prognosis, yet the precise mechanisms underlying these adverse clinical outcomes remain elusive. In this study, we analyzed tissue proteomic data from our osteosarcoma cohort to compare protein expression profiles between metastati...

Jia-Hao Zhang, Hai-Bin Xiang, Hao-Chen Mou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.